Breast cancer screening
Screening can be effective in reducing mortality from breast cancer. The evidence is now strong enough for the Working Group under the Chairmanship of Professor Sir Patrick Forrest to recommend a national mass screening programme.', and the Government has promised to set this up.
The Working Group was set up following publication of results from the Swedish Ostergotland and Kopparberg Trial.'. In this trial single-view radiographic screening of the breasts was offered at two-yearly intervals to women in their 40s and threeyearly intervals to older women. This resulted, by the seventh year of follow-up, in a reduction in mortality from breast cancer, within the invited population aged 40-74 years, of 30%. However, the beneficial effect was confined to those over 50 years at entry. These results are closely similar to those of the earlier Hospital Insurance Plan (New York) Trial", in spite of dissimilarities in screening methods. The American study had used the much less sensitive mammographic equipment available in the mid-1970s, physical examination in addition to mammographic screening, and screening on only four occasions at annual intervals although follow-up continued for a further 15 years. Both studies involved sending written invitations to attend screening, but in the American study only 65% of the invited women attended initially whereas in the Swedish study 89% attended. The studies used randomized controls and the observed mortality differences were statistically significant (P~O.01).
The design of both studies avoided lead-time bias and selfselection bias, which distort studies based solely on case-survival comparisons. Other studies, including the UK Trial of Early Detection of Breast Cancer, are in progress but have not yet accumulated sufficient data to report on mortality differences. Two Dutch studiest:", however, which are population-based but lack closely comparable controls, have added some further support to the case for screening by using a case-control method of analysis. They have found that women in Nijmegen and Utrecht were only about half as likely to die of breast cancer ifscreened than if unscreened. It is unlikely that self-selection could have been responsible for so marked an effect on mortality.
The evidence is strong by medical standards but not everyone is convinced. Some clinicians, who have only seen mammograms of inferior quality, are sceptical, but opinions tend to change when high-quality mammography is encountered. Other people are concerned that screening programmes may make women more worried about their health, more dependent on medical technology, more liable to undergo operations, and more likely to blame themselves or their doctors when advanced breast cancer afflicts them. These are disadvantages which must be weighed against the potential benefit. The number of deaths in England and Wales from breast cancer, 13000 per year", is high. (Compare it with the 2000 deaths caused each year by cervical cancer for which screening is already established.) Some cases develop before 50 years and others so late in life that they too would be unaffected by screening, but even if only one-fifth of women with the disease could be protected through screening from suffering advanced breast cancer, it would be a notable achievement.
Skrabanek, who has contested the morality of preventive medicine in general", has been the only persistent critic of the evidence in favour of breast cancer screening. He has pointed out anomalies observable when subgroups within the Swedish, American and Dutch trials are examined''. The laws of chance, however, predict that such differences are to be expected when multiple comparisons are made in studies of such a size, and his arguments do not invalidate the main trial conclusions.
Accepting the evidence that research programmes have proved successful, the next question is whether mass screening is feasible. It seems unlikely that a reliable programme can be established as speedily as the Government suggests. Equipment can be bought, but there are not enough radiologists and radiographers to operate a screening service. The Forrest Working Group estimates that the equivalent of 47 whole-time radiologists and 203 whole-time radiographers will be needed for a mass screening programme. Both an expansion in basic manpower training and new, specialized programmes of training in mammography are required, since even among established staff there are few with the necessary experience in mammography. Furthermore, radiologists may not be willing to scan the large numbers of mostly normal X-rays nor take on the clinical responsibilities involved. The creation and training of a cadre narrowly specializing in breast cancer screening may have to be considered. In the longer term, screening is feasible but it will require a high standard of management and careful monitoring if it is to be as successful as programmes run by enthusiastic research teams. Improvement of diagnostic facilities is a necessary first step towards screening and one that is desirable irrespective of a decision to finance mass breast cancer screening. The experience of screening shows that early cancers which are discernible by mammography lack the features of cancer described in older textbooks, but not infrequently cause vague thickening, distortion and discomfort. Since women are increasingly being encouraged through health education to look for and report promptly such suspicious changes in their breasts, the Health Service has a responsibility for providing prompt, sympathetic and reliable investigation, including usually mammograms, and a responsibility for ensuring that 0141-0768/87/ 011665-02/$02.00/0 e1987 The Royal
Society of Medicine
women are protected against the excessive use of biopsy. A shift towards earlier diagnosis need not and should not cause a permanent increase in surgical biopsy rates", The Forrest Working. Group recommends that a team consisting of a clinician, radiologist and a pathologist, each with a special interest in breast disease, supported by a radiographer and a nurse and/or receptionist, will be needed to support every local screening programme. These teams need to develop expertise now.
The Government has announced its decision to introduce screening at a time when no one can yet say what is the optimal programme and what exactly its costs and benefits will be. Major unresolved questions concern whether death from breast cancer is truly averted or only deferred, the extent to which benefit varies with age, the comparative effectiveness of different screening regimens, and whether the cost of screening can be reduced by more selective invitation. Knowledge will increase as more results of current screening programmes become available. The UK Triapo, which promises to publish first results in early 1988, will be particularly relevant as it will show the effect of screening against the UK background of breast disease, medical services and current attitudes towards them. It is of special interestbecause, in addition to assessing the value of screening by medical professionals, it is the only population-based study investigating whether the cheaper alternative of providing self-referral clinics for breast symptoms and teaching self-examination reduces breast cancer mortality.
Neither the Swedish nor the American study after seven years of follow-up found any mortality reduction for women under 50 years, and yet cancer occurring before that age is by no means rare and is particularly tragic. The reason why no benefit has been found in this age group is probably related to the fact that the preclinical detectable phase is shorter in younger women. This may partly be because development is more rapid, but it is also because detection is more difficult in premenopausal than in involuted breasts. Results from the American study have suggested but not proved that benefit from screening younger women may exist but take longer to become evident. A Canadian trial I I designed specifically to investigate the value of screening women under 50 years is in progress.
The method of screening which is most sensitive is now, beyond doubt, mammographic screening. Possibly it is over-sensitive. The Swedish trial! reported an excess of 21% in the number of invasive cancers detected in the screened group within the first seven years compared with the number detected in the comparison group, and it is possible that some of these would have been so slow-growing that they would never have troubled the patient had she not been screened. Another problem is that the prognosis for screen-detected breast cancers is not as good as for screen-detected cervical neoplasia. Less than 20% are noninvasive, in situ cancers, and in the Swedish study there were already axillary lymph node or distant metastases in 23% of the cases discovered in women who attended screening. More frequent screening would reduce the number of later-stage cases but, whilst the extra cost is easily calculated, it is unknown what marginal improvement in years of life saved could be achieved. The law of diminishing returns for added expenditure is certain to apply.
Beside the need for further information on the benefits of different screening regimens, the costs have to be analysed. It is a vain hope that breast cancer screening might pay for itself by reducing demand for treatment of advanced disease. Economists have estimated the cost of screening in Edinburgh and a separate group is studying costs in England both for screening and for the programmes which teach self-examination and provide self-referral clinics. An economic model based on the UK data will provide estimates of how costs and benefits would vary under different conditions affecting the type of screening, frequency, age range, invitation acceptance, diagnostic follow up and treatment regimen.
The cost per year oflife saved through screening is, according to the Forrest report1, of the order of £3000. Economic evaluation of other health service activities such as cervical cancer screening or kidney transplantation give comparable figures, but some services which are estimated to give more value in terms of quality adjusted years of life saved, such as hip replacement or coronary artery bypass operation for left main vessel disease, are still under-provided. Even the keenest of advocates of screening would be unhappy if screening were introduced at the expense of reducing other health services. Breast cancer screening will therefore require increased annual health service expenditure very roughly in the region of £20 million.
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